Clinical Trial Update: ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ARRx in combination with enzalutamide for metastatic castration-resistant prostate cancer was terminated, with results posted on May 13…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ARRx
• Xtandi (enzalutamide)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Prostate Cancer | Phase 1 | Status: TERMINATED | Results posted: 2025-05-13